Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial
Geert V.T. Roozen, Roos van Schuijlenburg, A Hensen, Jan Pieter R. Koopman, Olivia A. C. Lamers, Fiona J. A. Geurten, Jeroen Sijtsma, Els Baalbergen, Jacqueline J. Janse, Séverine Chevalley‐Maurel, Chanel M. Naar, Sascha Bezemer, Hans Kroeze, Huybert J. F. van de Stadt, Bram de Visser, Pauline Meij, Mara S. Tihaya, Emil Colstrup, Eva Iliopoulou, Helena M. de Bes-Roeleveld, Els Wessels, M. Y. Eileen C. van der Stoep, Chris J. Janse, Rajagopal Murugan, Blandine Franke‐Fayard, Meta Roestenberg
Abstract
Abstract Malaria vaccines consisting of metabolically active Plasmodium falciparum ( Pf ) sporozoites can offer improved protection compared with currently deployed subunit vaccines. In a previous study, we demonstrated the superior protective efficacy of a three-dose regimen of late-arresting genetically attenuated parasites administered by mosquito bite (GA2-MB) compared with early-arresting counterparts (GA1-MB) against a homologous controlled human malaria infection. Encouraged by these results, we explored the potency of a single GA2-MB immunization in a placebo-controlled randomized trial. Primary outcomes were safety and tolerability, time-to-parasitemia and protective efficacy. Humoral and cellular immunological results were considered secondary outcomes. Here we report the safe administration of GA2-MB with no breakthrough malaria and sterile protection in nine of ten participants at 6 weeks after a single immunization with 50 GA2-infected mosquitoes, compared with none of five mock-immunized participants, against a homologous controlled human malaria infection. Immunization increased circulating Pf -specific polyfunctional effector memory CD4 + T cells coexpressing tumor necrosis factor and interleukin-2. This unprecedented 90% protective efficacy after a single low-dose immunization holds great promise for the potency of GA2 immunization. Future studies should demonstrate whether GA2 is similarly efficacious in pre-exposed populations and whether the favorable safety profile reported here holds up in larger groups. ClinicalTrials.gov registration: NCT05468606 .